Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2024
Clinical Safety and Efficacy of Dual Wavelength Low-Level Light Therapy in Androgenetic Alopecia: A Double-Blind Randomized Controlled Study.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Thomas Meryl, Stockslager Max, Oakley John, Womble Thomas Matthew, Sinclair Rodney
Аннотация
BACKGROUND: The light-emitting diode cap being investigated is FDA cleared for the treatment of androgenetic alopecia (AGA).
OBJECTIVE: Evaluating 3 versions of a red and blue light LED cap: (1) 625- and 660-nm red light, (2) 425-nm blue light, and (3) both 425-nm blue light and 625- and 660-nm red light against sham.
PATIENTS AND METHODS: Twenty-six-week, multicenter, randomized, controlled, double-blinded study. Adults aged 18 to 65 years with AGA were randomized to an active device or sham and underwent 10-minute treatments daily.
RESULTS: One hundred sixty subjects were randomized. Ninety-one subjects were excluded for the per-protocol analysis. The per-protocol population included participants who completed 16 weeks of treatment, had no major protocol violations, and were at least 80% treatment compliant. Although the primary endpoint (mean change in non-vellus hair count from baseline to week 16) did not reach statistical significance in the individual study arms, in the pooled analysis (combining the 3 active study arms), there was a statistically significant ( p = .033) difference versus sham. The pooled study cap group achieved 28.5 more hairs per cm 2 when compared with sham.
CONCLUSION: The LED caps were well tolerated and increased hair density in patients with AGA.
OBJECTIVE: Evaluating 3 versions of a red and blue light LED cap: (1) 625- and 660-nm red light, (2) 425-nm blue light, and (3) both 425-nm blue light and 625- and 660-nm red light against sham.
PATIENTS AND METHODS: Twenty-six-week, multicenter, randomized, controlled, double-blinded study. Adults aged 18 to 65 years with AGA were randomized to an active device or sham and underwent 10-minute treatments daily.
RESULTS: One hundred sixty subjects were randomized. Ninety-one subjects were excluded for the per-protocol analysis. The per-protocol population included participants who completed 16 weeks of treatment, had no major protocol violations, and were at least 80% treatment compliant. Although the primary endpoint (mean change in non-vellus hair count from baseline to week 16) did not reach statistical significance in the individual study arms, in the pooled analysis (combining the 3 active study arms), there was a statistically significant ( p = .033) difference versus sham. The pooled study cap group achieved 28.5 more hairs per cm 2 when compared with sham.
CONCLUSION: The LED caps were well tolerated and increased hair density in patients with AGA.